As of 2026-09-21, the Relative Valuation of Summit Therapeutics Inc (SMMT) is (22.11) USD. This relative valuation is based on P/E multiples. With the latest stock price at 17.85 USD, the upside of Summit Therapeutics Inc based on Relative Valuation is -223.8%.
The range of the Relative Valuation is (20.39) - (25.54) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.0x - 23.8x | 21.4x |
| Forward P/E multiples | 15.7x - 23.9x | 19.8x |
| Fair Price | (20.39) - (25.54) | (22.11) |
| Upside | -214.2% - -243.1% | -223.8% |
| Date | P/E |
| 2026-09-18 | -16.63 |
| 2026-09-17 | -16.51 |
| 2026-09-16 | -16.12 |
| 2026-09-15 | -16.21 |
| 2026-09-14 | -17.16 |
| 2026-09-11 | -16.35 |
| 2026-09-10 | -15.84 |
| 2026-09-09 | -16.34 |
| 2026-09-08 | -16.10 |
| 2026-09-04 | -16.41 |
| 2026-09-03 | -15.96 |
| 2026-09-02 | -13.61 |
| 2026-09-01 | -13.20 |
| 2026-08-31 | -12.69 |
| 2026-08-28 | -12.79 |
| 2026-08-27 | -13.35 |
| 2026-08-26 | -13.26 |
| 2026-08-25 | -12.45 |
| 2026-08-24 | -11.86 |
| 2026-08-21 | -12.26 |
| 2026-08-20 | -11.58 |
| 2026-08-19 | -12.22 |
| 2026-08-18 | -11.95 |
| 2026-08-17 | -11.91 |
| 2026-08-14 | -12.44 |
| 2026-08-13 | -13.05 |
| 2026-08-12 | -14.07 |
| 2026-08-11 | -14.08 |
| 2026-08-10 | -13.86 |
| 2026-08-07 | -13.01 |
| 2026-08-06 | -12.62 |
| 2026-08-05 | -12.61 |
| 2026-08-04 | -12.82 |
| 2026-08-03 | -12.16 |
| 2026-07-31 | -12.13 |
| 2026-07-30 | -12.52 |
| 2026-07-29 | -11.93 |
| 2026-07-28 | -11.69 |
| 2026-07-27 | -12.21 |
| 2026-07-24 | -12.73 |
| 2026-07-23 | -13.96 |
| 2026-07-22 | -13.74 |
| 2026-07-21 | -13.63 |
| 2026-07-20 | -12.58 |
| 2026-07-17 | -12.87 |
| 2026-07-16 | -12.82 |
| 2026-07-15 | -14.04 |
| 2026-07-14 | -14.42 |
| 2026-07-13 | -14.26 |
| 2026-07-10 | -14.21 |